Core Insights - Helus Pharma has appointed Jill Conwell as Chief People Officer, effective immediately, to support the company's growth and clinical programs [1][3][9] Company Overview - Helus Pharma is a clinical stage pharmaceutical company focused on developing novel serotonergic agonists (NSAs) aimed at addressing mental health conditions such as depression and anxiety [5][6] - The company is currently advancing its clinical pipeline, including HLP003 in Phase 3 for major depressive disorder and HLP004 in Phase 2 for generalized anxiety disorder [6] Leadership Experience - Jill Conwell brings over 20 years of leadership experience in the life sciences sector, with a strong background in organizational strategy, talent development, and corporate communications [2][4] - Conwell has held senior roles at Aclaris Therapeutics, Idera Pharmaceuticals, and Shire Pharmaceuticals, contributing to organizational growth and transformation [3][4] Strategic Goals - The appointment of Conwell is expected to enhance Helus Pharma's ability to attract top talent and foster a collaborative culture as the company prepares for its next growth phase [3][4] - Conwell expressed enthusiasm about joining Helus Pharma at a critical time, emphasizing the company's innovative approach to mental health treatment [4]

Group 1 - The company is responsible for the development of transcript-related projects [1] - It publishes thousands of quarterly earnings calls per quarter and is expanding its coverage [1]

Core Insights - The company, Helus, is presenting results from its Phase II study in generalized anxiety disorder (GAD) and has two proprietary clinical programs, 003 and 004, with positive Phase II data [1][2] Company Overview - Helus has received FDA breakthrough therapy status for its lead program, 003, which is currently in Phase III for adjunctive treatment of major depressive disorder (MDD) [2] - The company has a strong intellectual property portfolio with over 350 filed patents, of which 100 are granted [2] Pipeline and Upcoming Catalysts - The pipeline includes two late-stage clinical development programs, 003 and 004, with a major catalyst expected in Q4 of this year, specifically the top line data from the first Phase III trial in MDD [3] - The company is focusing on the top line data from 004 in GAD, which is expected to be discussed in detail [3] Clinical Data Highlights - The company believes that 004 has an emerging best-in-class profile, supported by positive outcomes from both Phase I and Phase II studies [4] - In the Phase II study for GAD, there was a clinically meaningful 10-point reduction in the Hamilton Anxiety Rating Scale (HAM-A) at 6 weeks, with significant results observed as early as day 2 [4]

Core Insights - Helus Pharma's shares declined following the announcement of topline results from a Phase 2 study for HLP004, a potential treatment for generalized anxiety disorder (GAD) [1] Anxiety Disorder Data - The Phase 2 study involved 36 patients who were randomized to receive either HLP004 or a placebo, showing a 10.4-point improvement in anxiety symptoms beyond standard care treatments [2] - The drug demonstrated a favorable tolerability profile with no serious adverse events or suicidality-related safety signals [2] Helus Pharma Drug Shows Durable Remission - At six months, the study population had 67% responders and 39% remitters [3] - In the 20 mg dosing arm, 59% met the criteria for response and 32% for remission, while the 2 mg arm had a 30% responder and remitter rate at week 6 [3] Competition - AtaiBeckley Inc. reported topline results from a Phase 2a trial of EMP-01 for Social Anxiety Disorder, with 49% of patients rated as "very much improved" or "much improved," compared to 15% in the placebo group [4] Helus Pharma's Technical Analysis - The stock is trading 10.43% below its 20-day simple moving average (SMA) and 12.5% below its 100-day SMA, indicating a bearish trend [5] - Over the past 12 months, shares have decreased by 5.2% and are closer to their 52-week lows than highs [5] Additional Technical Indicators - The RSI is at 50.00, indicating neutral territory, while the MACD is at 0.10, below its signal line at 0.15, suggesting bearish pressure [6] HELP Price Action - Helus Pharma shares were down 33.19% at $6.41 at the time of publication, with key resistance at $8.00 and key support at $7.50 [7]

Core Insights - Helus Pharma announced topline results from a Phase 2 study of HLP004 for treating generalized anxiety disorder (GAD), showing significant improvement over standard treatments [5][9][11] Company Overview - Helus Pharma is a clinical-stage pharmaceutical company focused on developing novel serotonergic agonists (NSAs) for serious mental health conditions [14][15] - The company operates in Canada, the United States, the United Kingdom, and Ireland [16] Study Details - The Phase 2 study involved 36 patients with moderate-to-severe GAD who were symptomatic despite ongoing standard of care (SoC) antidepressant therapy [7][9] - Participants received either 20 mg or 2 mg of HLP004, with a follow-up period extending to one year [7][9] Efficacy Results - A statistically significant improvement of approximately 10 points on the Hamilton Anxiety Rating Scale (HAM-A) was observed at 6 weeks, with durable effects sustained for at least 6 months [9][17] - At six months, 67% of participants were responders and 39% were in remission [9][17] Treatment Profile - HLP004 demonstrated a rapid onset of action, with acute effects lasting around 90 minutes and patients ready for discharge within approximately three hours [9][17] - The treatment was generally well-tolerated, with no serious adverse events reported [9][17] Future Developments - The company plans to advance the development of HLP004 and is also preparing to release data on HLP003, aimed at major depressive disorder, in Q4 2026 [12][15]

Core Viewpoint - Helus Pharma has appointed Dr. Freda Lewis-Hall to its Board of Directors and as Chair of the Scientific Advisory Committee, aiming to enhance its clinical development strategy and regulatory engagement for its novel serotonergic agonist portfolio [2][6]. Company Overview - Helus Pharma is a clinical stage pharmaceutical company focused on developing novel serotonergic agonists (NSAs) to address serious mental health conditions such as depression and anxiety [9][10]. - The company operates in Canada, the United States, the United Kingdom, and Ireland [11]. Leadership Appointment - Dr. Freda Lewis-Hall brings over 40 years of experience in clinical care, research, and corporate leadership, having previously served as Executive Vice President and Chief Medical Officer at Pfizer [3][4]. - Her role will involve providing leadership in scientific, clinical, and regulatory governance across Helus' portfolio, advising on discovery opportunities and clinical development strategies [6][7]. Clinical Development Focus - Helus Pharma is currently developing HLP003, a proprietary NSA in Phase 3 clinical development for major depressive disorder, which has received Breakthrough Therapy Designation from the U.S. FDA [10]. - HLP004, another proprietary NSA, is in Phase 2 for generalized anxiety disorder [10]. Strategic Goals - The company aims to improve the treatment landscape for mental health through its innovative NSAs, focusing on delivering meaningful outcomes for patients and long-term value for stakeholders [6][10].

Core Viewpoint - Helus Pharma announced positive results from a Phase 2a clinical trial of SPL026, a novel serotonergic agonist for treating major depressive disorder, demonstrating significant reductions in depressive symptoms compared to placebo [2][3][7]. Study Results - The Phase 2a trial met its primary endpoint, showing a mean difference of -7.35 in MADRS scores at two weeks for SPL026 compared to placebo, with a p-value of 0.023 [3][7]. - Significant reductions in depressive symptoms were observed as early as one week post-dosing, with effects lasting up to six months in some participants [3][4]. - Response rates for SPL026 were 35% at Week 2, compared to 12% for placebo, while remission rates were 29% for SPL026 versus 12% for placebo [4][7]. Treatment Safety and Efficacy - SPL026 was generally well tolerated, with no serious treatment-related adverse events reported [3][4]. - The study involved 34 participants with a mean age of 32.8 years, predominantly white, who had experienced depression for an average of 10.5 years [8]. Future Developments - Helus Pharma plans to advance HLP004, another proprietary NSA, for generalized anxiety disorder, with topline data expected in Q1 2026 [5][11]. - The findings from the SPL026 trial support the potential of short-acting serotonergic agonists in mental health treatments, reinforcing the company's strategy for developing novel serotonergic agonist molecules [5][7]. Company Overview - Helus Pharma is a clinical-stage pharmaceutical company focused on developing proprietary NSAs aimed at addressing mental health conditions such as depression and anxiety [10][11]. - The company operates in multiple regions, including Canada, the United States, the United Kingdom, and Ireland [12].

Core Insights - Helus Pharma announced positive results from a Phase 2a clinical trial of SPL026 for major depressive disorder, showing significant reductions in depressive symptoms compared to placebo [2][3][7] Study Results - The study met its primary endpoint with a mean difference in MADRS score of -7.35 at two weeks, indicating a statistically significant reduction in depressive symptoms [3][7] - Participants treated with SPL026 showed reductions in symptoms as early as one week, with effects lasting up to six months in some cases [3][4] - Response rates for SPL026 were 35% compared to 12% for placebo, and remission rates were 29% versus 12% [4][7] Treatment Efficacy - A single 21.5 mg dose of SPL026 was well tolerated, with no serious adverse events reported [3][4] - The treatment effects were comparable to other longer-duration interventions, suggesting potential cost-effectiveness [4][5] Future Developments - Helus Pharma is advancing HLP004, another proprietary serotonergic agonist, with topline data expected from its Phase 2 study in generalized anxiety disorder in Q1 2026 [5][11] - Insights from the SPL026 trial are informing the development of HLP004, which aims to optimize pharmacology and scalability [5][11] Company Overview - Helus Pharma is focused on developing novel serotonergic agonists to address unmet needs in mental health, including depression and anxiety [10][11] - The company operates in multiple regions, including Canada, the United States, the United Kingdom, and Ireland [12]

Core Viewpoint - Helus Pharma is advancing its clinical programs with a strong financial position and is well-positioned for upcoming clinical milestones, particularly in the treatment of mental health disorders [2][3]. Financial Highlights - As of December 31, 2025, the company reported cash totaling US$195.1 million before adjustments for post-quarter events [7]. - The net loss for the quarter ended December 31, 2025, was US$42.7 million, compared to a net loss of US$7.5 million in the same period last year [16]. - Cash-based operating expenses for the quarter were US$36.7 million, up from US$20 million in the same period last year [16]. Business and Pipeline Highlights - The company is focused on a differentiated neuroscience portfolio, with ongoing clinical programs HLP003 in Phase 3 for major depressive disorder and HLP004 in Phase 2 for generalized anxiety disorder [3][8]. - Upcoming topline data readout from the Phase 2 study evaluating HLP004 in generalized anxiety disorder is expected in Q1 2026 [5]. - The HLP003 Phase 3 program continues with pivotal studies APPROACH™ and EMBRACE™, with topline data anticipated in Q4 2026 [9]. Leadership and Strategic Focus - A leadership transition has been completed with the appointment of Michael Cola as CEO, aimed at leading the company towards a potential first commercial product launch [8]. - The company has rebranded to "Helus Pharma" and is focusing on engineered serotonergic agonists designed for controlled pharmacokinetics and potential commercial scalability [8]. Intellectual Property and Market Position - Helus Pharma is expanding and defending its intellectual property portfolio, which supports multiple programs and provides protection for lead programs HLP003 and HLP004 until at least 2041 [8].

Core Viewpoint - Helus Pharma has appointed Michael Cola as CEO at a pivotal moment for the company, as it advances its next-generation mental health therapies and approaches critical clinical milestones [2][3]. Company Developments - Helus Pharma is progressing its clinical pipeline, with HLP004 Phase II data expected to be released this quarter and HLP003 Phase III topline data anticipated in Q4 2026 [2][6]. - The company has submitted over 350 patent applications globally and has received more than 100 patents, indicating a strong intellectual property portfolio [2]. - Helus Pharma is focused on addressing severe mental health disorders through differentiated projects and is transitioning from early clinical development to late-stage execution [2][6]. Leadership Appointment - Michael Cola brings over 30 years of experience in neuroscience, rare diseases, and specialty pharmaceuticals, making him a suitable leader for Helus [3][4]. - Cola's previous achievements include transforming Shire into a leader in the CNS field and significantly increasing its market value from $5 billion to $20 billion [4][5]. - Cola has also held leadership roles in various companies, contributing to successful clinical transitions and product launches [5][6]. Company Background - Helus Pharma, established in 2019, focuses on developing proprietary new serotonin agonists (NSAs) aimed at improving mental health recovery [8]. - The company is currently developing two proprietary NSAs: HLP003, in Phase III for major depressive disorder, and HLP004, in Phase II for generalized anxiety disorder [8]. - Helus Pharma aims to address the significant unmet treatment needs of patients with depression, anxiety, and other mental health disorders [8].